Product Specifications: Lyophilized Powder (>99% purity) in 3ml vial. *Requires Reconstitution ** Available for bulk custom order with 57 Cap/Crimp colors to choose from.
Application: Research peptide evaluated in iimmunomodulation, infectious disease treatment, cancer therapy, neurological disorders, and wound healing.
Chemical Formula: C129H215N33O55
CAS Number: 62304-98-7
Molecular Weight: ~3108.3 g/mol
Concentration: ≥99%
Thymosin-alpha-1 (Tα1) is an immunostimulatory peptide that was initially isolated from thymus tissue. As a biological response modifier, it has demonstrated broad effects on various cellular processes and immune functions. Research into Tα1 spans multiple therapeutic areas, with significant progress made in understanding its mechanisms of action and potential clinical applications.
Primary Research Areas
1. Immunomodulation
Tα1 is primarily being researched for its immunomodulatory properties, making it potentially valuable for treating conditions characterized by immune dysfunction.
- Mechanism of Action: Tα1 modulates immune responses by enhancing T-cell function, promoting dendritic cell maturation, and influencing cytokine production.
- Target Conditions: Immunodeficiency disorders, autoimmune diseases, and as an immune enhancer in various conditions requiring immune system support.
- Clinical Applications: Being researched as a therapeutic agent for diseases with evident immune dysfunction, with potential applications as an adjuvant therapy to enhance immune responses.
2. Infectious Diseases
A significant focus of Tα1 research is on its antiviral and antibacterial properties, particularly for various viral infections.
- Hepatitis B and C: Tα1 is commonly used as an immune enhancer in the treatment of hepatitis B and hepatitis C viral infections. The FDA has evaluated Tα1 for potential use in these conditions.
- COVID-19 and SARS: Research indicates that Tα1 could improve lymphocyte functionality and serve as a beneficial therapeutic alternative as an adjuvant in SARS-CoV2 treatment. However, some studies suggest that Tα1 may have no benefit on restoring CD4+ and CD8+ T cell counts or on virus clearance in COVID-19 patients.
- Sepsis: While some clinical trials have shown that Tα1 improves survival in patients in intensive care units being treated for sepsis, a recent trial found no clear evidence to suggest that thymosin α1 decreases 28-day all-cause mortality in adults with sepsis.
- Other Infectious Diseases: Tα1 has been investigated for various indications related to acute infection, including bone marrow transplant-related infections, and an Expert Consensus has been published on the clinical application of Tα1 in infectious diseases and critical care medicine.
3. Cancer Treatment
Tα1 has been extensively researched as an adjunct therapy for various types of cancer.
- Mechanism in Cancer: Tα1 has been shown to decrease tumor cell growth both in vitro and in vivo and has demonstrated therapeutic usefulness in several types of cancer.
- Specific Cancer Applications:
- Lung cancer: The effectiveness of thymosin drugs in the treatment of lung cancer has been demonstrated in numerous studies .
- Hepatocellular carcinoma: Recent research shows that Tα1 combined with lenvatinib plus sintilimab is an effective and safe therapeutic regimen in unresectable hepatocellular carcinoma.
- Other cancers: Studies have investigated Tα1 for malignant melanoma, colorectal cancer, and glioblastoma.
- Combination Therapies: Tα1 shows promising results when combined with other biological response modifiers or chemotherapy agents. For example, a treatment regimen combining PD-1 inhibitor with SBRT, GM-CSF, and thymosin may offer a promising treatment strategy for patients with metastatic triple-negative breast cancer (mTNBC) and other metastatic solid cancers.
4. Neurological Disorders
An emerging area of research explores Tα1's therapeutic potential for various neurological conditions.
- Neurogenesis and Cognitive Function: Research suggests that peripheral Tα1 contributes to neurogenesis and cognition, probably through a systemic Th1 bias, as well as neuroprotection.
- Traumatic Brain Injury: Studies have shown that Tα1 improves neurological deficits after blast traumatic brain injury (bTBI) in rats, potentially related to the inhibition of tau pathology.
- Multiple Sclerosis: Research reveals a deficient ability of B cells from MS patients to differentiate into regulatory subsets, and Tα1 has shown potential to expand deficient IL-10-producing regulatory B cells, unveiling a novel anti-inflammatory approach.
- Other Neurological Applications: Ongoing research is investigating Tα1's potential applications in Parkinson's disease and Alzheimer's disease, although these areas require further study.
5. Wound Healing
Tα1 has demonstrated significant potential in promoting wound healing through multiple mechanisms.
- Angiogenesis and Cell Migration: Tα1 has been shown to stimulate endothelial cell migration and angiogenesis.
- Wound Repair Acceleration: When given either topically or intraperitoneally, Tα1 accelerated wound healing in experimental models, demonstrating that it promotes angiogenesis and wound healing.
- Tissue Repair Mechanisms: The regenerative properties of Tα1 are being investigated for applications in tissue repair and wound healing.
- Diabetic Wound Treatment: Research has shown that Tα1 pre-treatment significantly enhanced diabetic wound resilience against biofilm adherence.
- Collagen Synthesis and Tissue Strength: Tα1 has been associated with enhanced collagen synthesis, improved tissue strength, and reduced inflammation in wound healing contexts.
References:
Goldstein, A. L., & White, A. (1966). Thymosin and the endocrine role of the thymus. Clinical and Experimental Immunology, 1(3), 241-255.
Saha, B., Jyothi, P. R., & Chandrasekar, B. (2001). Thymosin alpha-1: A peptide with immunoregulatory and anti-inflammatory properties. Journal of Leukocyte Biology, 70(2), 161-168. https://doi.org/10.1189/jlb.70.2.161
Romani, L., & Puccetti, P. (2017). Thymosin alpha-1: A peptide with immunotherapeutic properties. Journal of Immunology Research, 2017, 1-11. https://doi.org/10.1155/2017/9584634
Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes. Researchers should handle all peptides with care and adhere to strict safety guidelines during experiments. Only qualified professionals with appropriate expertise should manage and handle this product. The distributor, manufacturer, and seller of this product are not responsible for misuse or any resulting consequences. By accessing this product, you consent to comply with these terms and conditions.
